AKACID Plus, a novel polymeric guanidine with broad antimicrobial activity against multiantibioticresistant bacterial strains, was used in the present study as a room disinfectant. Disinfection of closed rooms experimentally contaminated with antibiotic-susceptible and multiresistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Escherichia coli was performed using AKACID Plus at concentrations of 0.1, 0.25, and 0.5% for 100 min. Bacterial suspensions were distributed on plastic and stainless steel plates and placed in a test room. Recovery of the test microorganisms was determined before nebulizing, 60 and 100 min after initiation, and 4 h after the end of room disinfection by a simple swab-rinse technique. The swab-rinse method demonstrated a dose-and time-dependent effectiveness of AKACID Plus in eradicating S. aureus, E. coli, and P. aeruginosa on plastic and stainless steel plates. Nebulized 0.5% AKACID Plus was successful in eliminating all hospital pathogens within 340 min. After the use of 0.25% AKACID Plus, MRSA was still detectable on microbial carrier plates. The test concentration of 0.1% AKACID Plus achieved a significant reduction of S. aureus and P. aeruginosa on plastic and stainless steel plates but was sufficient to eradicate only E. coli. These results suggest that nebulized AKACID Plus at a concentration of 0.5% is a potent substance for eradication of pathogenic organisms in the hospital setting.Data from the World Health Organization show that in the United States some 14,000 individuals are infected and die each year as a result of drug-resistant microbes acquired in hospitals. In intensive care units, nosocomial infections increase the total costs by $3,306 and the length of stay by 18.2 days per patient (3). Methicillin-resistant Staphylococcus aureus (MRSA) and multiresistant gram-negative rods are wreaking havoc in hospital wards around the world (24). Herr et al. (12) determined additional costs of hygiene measures (barrier precautions, isolation, and decontamination) required for MRSA carriers in German hospitals by averaging 372 euros for one MRSA patient hospital-day and 9,263 euros per MRSA case. Already, MRSA and extended-spectrum-beta-lactamase-producing Enterobacteriaceae have spread outside hospitals. The epidemic spread of resistant bacteria and resistance genes is supported primarily by selection of resistant microorganisms by frequent application of antimicrobial agents, inadequate or inappropriate therapy, use of broad-spectrum antibiotics as growth promoters for animal foods and as pesticides for agriculture (16), and, because of lack of general hygiene measures, transmission of hospital strains to other patients and medical staff (2,10,18,20).Clearly, preventive measures for the termination of this mode of selection and transmission are of vital importance. In hospital and health care settings, antiseptics and disinfectants are essential tools for infection control and aid in prevention of nosocomial infections (5, 9). By acting rapidly, disinfectants can p...